Genmab A/S (OTCMKTS:GNMSF) Announces Quarterly Earnings Results, Beats Expectations By $2.15 EPS

Genmab A/S (OTCMKTS:GNMSF) released its quarterly earnings data on Thursday. The company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $2.15, Zacks reports. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.20 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%.

Genmab A/S Stock Performance

Shares of OTCMKTS:GNMSF remained flat at $538.00 during trading on Friday. 100 shares of the stock were exchanged, compared to its average volume of 5,854. The firm’s 50-day moving average price is $387.72 and its 200-day moving average price is $309.34. Genmab A/S has a 1 year low of $232.34 and a 1 year high of $581.00. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The company has a market capitalization of $33.12 billion, a PE ratio of 42.20 and a beta of 0.64.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.

Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.